Age-Related Differences in Circulating Proteins After Influenza and Herpes Zoster Vaccination

Kilic, G.

Taks, E.J.M.

Helder, L.S.

Dulfer, E.A.

Geckin, B.

van Emst, L.

Lemmers, H.

Berrè, S.

Biswas, A.

Ozturk, M.

Negishi, Y.

Burny, W.

Buonocore, S.M.

ten Oever, J.

Mhlanga, M.M.

Netea, M.G.

The INFLUENZA-SHINGRIX study aims to characterize age-dependent immune responses following an adjuvanted herpes zoster vaccine (RZV) and an inactivated tetravalent influenza vaccine (IIV4) administration and to identify immunological features associated with their distinct effectiveness profiles. We conducted a randomized, partially placebo-controlled, open-label clinical study in young (18–35 years) and older (≥60 years) adults. Young participants were randomized 3:3:1:1 to receive RZV, IIV4, RZV-placebo, or IIV4-placebo, while older adults were randomized 1:1 to receive RZV or IIV4. In this collection, the measurement of 92 circulating proteins using the Olink Target 96 Inflammation panel was shared. The sample collection for plasma proteomics analysis was done between September 2021 and February 2023. The data were provided as NPX values generated by the Olink proprietary processing pipeline.